HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Hepatitis B surface antigen loss/seroconversion, considered to be the ideal outcome of
chronic hepatitis B virus (HBV) infection, occurs spontaneously at a low rate in inactive
carriers.
The researchers aim to investigate the ability of peginterferon alpha-2a to achieve surface
antigen loss/seroconversion therapy in inactive carriers with persistently normal alanine
aminotransferase (ALT) levels, undetectable HBV DNA and low surface antigen levels, who would
not generally be considered candidates for therapy.